NeoGenomics NEO Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$99.21M-27.9% | -$108.03M-37.2% | -$113.47M-46.0% | -$104.04M-32.5% | -$77.59M+7.9% | ||
| $35.49M-8.0% | $36.07M-7.7% | $37.14M-4.4% | $37.96M-1.6% | $38.56M+0.7% | ||
| $40.2M+44.0% | $41.32M+65.6% | $41.6M+76.2% | $31.3M+32.6% | $27.92M+36.4% | ||
| —— | —— | —— | $3.33M-48.9% | $2.82M-68.5% | ||
| $13.69M+15.9% | $6.18M-69.4% | $1.97M— | $4.45M— | $11.82M— | ||
| —— | —— | —— | $10.68M— | $9.56M— | ||
| -$5.12M-88.1% | -$4.69M-17.2% | -$2.16M-43.4% | $8.7M+196% | -$2.72M+69.0% | ||
| —— | —— | —— | —— | —— | ||
| -$3.27M-141% | -$1.56M-123% | $7.28M— | $8.28M— | $7.96M— | ||
| -$693K— | -$323K— | —— | —— | —— | ||
| $31.02M-7.2% | $31.75M-5.1% | $32.48M-4.1% | $33.21M-3.2% | $33.45M-3.6% | ||
| —— | —— | —— | —— | -$5.66M+22.9% | ||
| $22.42M— | $5.23M— | $13.69M— | —— | —— | ||
| $27.51M-31.2% | $27.01M-34.2% | $30.74M-15.8% | $33.22M+10.8% | $39.98M+63.8% | ||
| $12M-71.3% | $20.06M-62.8% | $26.19M-63.6% | $24.48M-72.8% | $41.87M-54.4% | ||
| -$20.9M— | -$12.34M— | —— | —— | —— | ||
| -$325K-107% | $962K-79.3% | $1.22M-76.7% | $1.63M-72.4% | $4.78M+18.6% | ||
| —— | —— | —— | -$199.62M-3,487% | $4.78M+19.7% | ||
| -$209.45M-1,567% | -$216.79M-984% | -$207.27M-472% | -$200.36M-404% | $14.28M-74.6% | ||
| $2.12M-37.6% | $1.69M-55.8% | $3.38M-0.5% | $3.4M+0.4% | $3.4M+0.6% | ||
| $515K— | $515K— | —— | —— | —— | ||
| $31.02M-7.2% | $31.75M-5.1% | $32.48M-4.1% | $33.21M-3.2% | $33.45M-3.6% | ||
| $35.49M-8.0% | $36.07M-7.7% | $37.14M-4.4% | $37.96M-1.6% | $38.56M+0.7% | ||
| -$5.12M-88.1% | -$4.69M-17.2% | -$2.16M-43.4% | $8.7M+196% | -$2.72M+69.0% | ||
| —— | —— | —— | $3.33M-48.9% | $2.82M-68.5% | ||
| —— | —— | —— | —— | -$5.66M+22.9% | ||
| -$3.27M-141% | -$1.56M-123% | $7.28M— | $8.28M— | $7.96M— | ||
| —— | $500K— | $375K— | $250K— | $125K— | ||
| $12M-71.3% | $20.06M-62.8% | $26.19M-63.6% | $24.48M-72.8% | $41.87M-54.4% | ||
| —— | —— | —— | —— | —— | ||
| —— | $30K+115% | -$26K+82.1% | -$82K+15.5% | -$138K-185% | ||
| —— | —— | —— | —— | -$5.66M+22.9% | ||
| $6.89M-15.1% | $6.75M-24.4% | $6.94M-26.1% | $7.49M-20.2% | $8.11M-12.9% | ||
| —— | $2.07M— | $1.55M— | $1.03M— | $516.5K— | ||
| —— | $6.4M+937% | $4.95M+111% | $3.51M-13.8% | $2.06M-64.4% | ||
| $515K— | $515K— | —— | —— | —— | ||
| —— | —— | —— | —— | -$33.18M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does NeoGenomics generate?
- NeoGenomics (NEO) generated $22.4M in operating cash flow over the trailing twelve months.
- What is NeoGenomics's free cash flow?
- After $27.5M of capital expenditures, NeoGenomics's free cash flow was -$51.3M over the trailing twelve months, down 19.8% year over year.
- Where does NeoGenomics's cash flow data come from?
- Every line is extracted from NeoGenomics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
